Mölnlycke Health Care and Zhende Medical form pioneering joint venture to expand access to advanced wound care solutions in China
· First-of-its-kind joint venture combines the two companies’ wound care portfolios to deliver a broader wound care offering in China · Commercial reach spans nearly 10,000 hospitals, 200,000 pharmacies and a powerful eCommerce set-up across China · Positioned to capture opportunities in China’s fast-growing advanced wound care marketGothenburg, Sweden, and Shanghai, China. 21 May 2026. Mölnlycke Health Care (“Mölnlycke[®]”), a global leader in MedTech and advanced wound care solutions, and Zhende Medical, a leading supplier of medical care and protection in China, today announce the
Gothenburg, Sweden. 27 January 2026. Mölnlycke Health Care, a global leader in MedTech, headquartered in Gothenburg, Sweden, is celebrating the production of 100 million ProcedurePak® trays at the company’s production sites in the Czech Republic.
This achievement reflects Mölnlycke’s commitment to more efficient and sustainable surgical care. With 100 million trays delivered, Mölnlycke has facilitated millions of procedures across the world, helping hospitals improve operating room workflows and consistency. Customised ProcedurePak trays can reduce surgical preparation time by up to 40%
Changshu, China, and Gothenburg, Sweden. 5 November 2025. Mölnlycke Health Care, a global leader in MedTech, headquartered in Gothenburg, Sweden, is celebrating the commencement of its new wound care manufacturing site in Changshu, China. This strategic investment marks a milestone in Mölnlycke’s growth journey and the beginning of localised manufacturing in one of the world’s fastest-growing MedTech markets.“Our site in Changshu marks another step forward in Mölnlycke’s ambition to manufacture products closer to where they are sold. It reflects our glocal approach, combining global
Gothenburg, Sweden. 21 August 2025. Mölnlycke[®], a world-leading MedTech company, has once again been recognised as a global sustainability leader, earning the prestigious EcoVadis Platinum medal for the second year in a row. This accolade places Mölnlycke in the top 1% of all companies assessed worldwide by EcoVadis, a trusted platform used across industries to evaluate environmental, social and ethical performance.
Mölnlycke’s scores improved across every category of the EcoVadis assessment compared to last year, underscoring the company’s dedication to driving meaningful change.
New white paper calls for integration of environmental, human and economic metrics in sustainability assessments of medical technologiesGothenburg, Sweden, 12 June 2025. At CleanMed Europe 2025, Mölnlycke[®] has unveiled a white paper urging a unified European approach to sustainability in healthcare. The paper highlights the need for a broader definition of sustainability assessments for medical technology.
Current assessment frameworks focus mainly on environmental indicators, often overlooking human and economic factors. Mölnlycke warns this narrow view can hinder progress and lead
Gothenburg, Sweden. 4 June 2025. Mölnlycke is pleased to announce the election of Filippa Stenberg as a deputy board member to its Board of Directors, as of 22 May 2025.Filippa brings over a decade of experience in active ownership with a focus on healthcare investments. She currently serves as a Managing Director of Patricia Industries, part of Investor AB, where she has been instrumental in driving value creation in several globally leading companies.
“We are delighted to welcome Filippa to the Mölnlycke Board,” said Karl-Henrik Sundström, Chairman of the Board. “Her energy, expertise
Gothenburg, Sweden. 13 May, 2025. Mölnlycke’s long-term net zero greenhouse gas (GHG) emission reduction targets have been validated by the Science Based Targets initiative (SBTi), following prior validation of the company’s near-term GHG emission reduction targets.Mölnlycke has committed to reaching net zero greenhouse gas emissions across the value chain by 2050. Specifically, the company has committed to reducing absolute Scope 1 and 2 GHG emissions by 90% by 2050 compared to the 2021 base year, and to reducing Scope 3 GHG emissions by 97% per tonne of sold product within the same